about
Premature termination of reprogramming in vivo leads to cancer development through altered epigenetic regulation.Investigation of Rare Single-Nucleotide PCDH15 Variants in Schizophrenia and Autism Spectrum Disorders.Inhibition of indoleamine 2,3-dioxygenase activity enhances the anti-tumour effects of a Toll-like receptor 7 agonist in an established cancer model.Mutation screening of GRIN2B in schizophrenia and autism spectrum disorder in a Japanese populationResequencing and Association Analysis of Six PSD-95-Related Genes as Possible Susceptibility Genes for Schizophrenia and Autism Spectrum Disorders.Rare loss of function mutations in N-methyl-D-aspartate glutamate receptors and their contributions to schizophrenia susceptibility.Behavior of leucine-rich repeat-containing G-protein coupled receptor 5-expressing cells in the reprogramming process.Genetic and animal model analyses reveal the pathogenic role of a novel deletion of RELN in schizophreniaAuthor Correction: Proteomic analysis of lymphoblastoid cell lines from schizophrenic patientsProteomic analysis of lymphoblastoid cell lines from schizophrenic patientsComparative Analyses of Copy-Number Variation in Autism Spectrum Disorder and Schizophrenia Reveal Etiological Overlap and Biological InsightsEffect of intranasal oxytocin on the core social symptoms of autism spectrum disorder: a randomized clinical trialGeneration and analysis of novel Reln-deleted mouse model corresponding to exonic Reln deletion in schizophreniaIn Vitro Modeling of the Bipolar Disorder and Schizophrenia Using Patient-Derived Induced Pluripotent Stem Cells with Copy Number Variations of PCDH15 and RELNSingle-cell trajectory analysis of human homogenous neurons carrying a rare RELN variantThree lines of induced pluripotent stem cells derived from a 15q11.2-q13.1 duplication syndrome patientCell body shape and directional movement stability in human-induced pluripotent stem cell-derived dopaminergic neuronsCharacterization of a schizophrenia patient with a rare RELN deletion by combining genomic and patient-derived cell analysesQuantitative facial expression analysis revealed the efficacy and time course of oxytocin in autism
P50
Q34404346-F7A58BB0-FCAE-45B0-B08C-78B658D5469CQ35983713-2B6B2111-2261-4985-8683-5197D6810685Q38947206-958324E1-0071-42C7-9A46-B1A4391D964BQ41063908-BAAFD54C-E000-42FE-AD26-50019FA29EB6Q41868330-B0B5AC37-56CA-4A55-B6AF-60C934EC3753Q47873505-76B7906B-4113-40D7-82A9-C0942E5787E8Q51139747-22682565-940A-416C-824F-551B965706A7Q58695557-8B826C96-18D8-48C7-A154-4A6512273FA5Q64069496-7AFD0686-2B75-4FD5-A50A-032862C17A42Q64099763-0CB14526-E60D-42C2-93FC-39AEA070EC03Q64122202-D2BBA481-A1DF-45CB-A056-ABDD7BF22F55Q89326875-F3B8D343-8C78-4302-9B71-F85E0CA6F318Q89743437-5739A8C4-83F0-4A8C-83B6-BC84F5312FE3Q90196682-6D244493-078B-4511-BB47-CE233F7BE4BDQ90322658-7CD098DD-201A-48CC-9A49-BEC0FB4F29DCQ91138785-86352B15-64D4-48CD-AC60-0DA8AA187CA7Q91522544-AF9A1C6D-4E9A-4984-89CD-B3CF03289BD4Q92056311-7901504B-1BAB-488B-9569-0617F54856B6Q92079941-8443189E-3CB9-4BA9-B41E-0BA2F994AB70
P50
description
researcher
@en
wetenschapper
@nl
name
Yuko Arioka
@en
Yuko Arioka
@nl
type
label
Yuko Arioka
@en
Yuko Arioka
@nl
prefLabel
Yuko Arioka
@en
Yuko Arioka
@nl
P31
P496
0000-0002-1792-8812